Rostock, Germany

Niklas Elmar Neuschaefer

USPTO Granted Patents = 8 

Average Co-Inventor Count = 7.0

ph-index = 4

Forward Citations = 85(Granted Patents)


Company Filing History:


Years Active: 2017-2024

Loading Chart...
8 patents (USPTO):Explore Patents

Title: Innovations by Niklas Elmar Neuschaefer

Introduction

Niklas Elmar Neuschaefer is a prominent inventor based in Rostock, Germany. He has made significant contributions to the field of cell therapy manufacturing, holding a total of eight patents. His work focuses on developing innovative systems that enhance the efficiency and effectiveness of patient-specific treatments.

Latest Patents

One of his latest patents is titled "Devices and disposables for patient-specific cell therapy manufacturing." This invention involves a system that includes a sample processing unit with an input and output port connected to a rotating container. The system is designed to apply centrifugal force to a sample, allowing for the separation of its components. Another notable patent is the "Single use tubing set for making genetically modified donor cells for reinfusion into a patient." This system also features a sample processing unit and a sample separation unit, which work together to control fluid flow and separate labeled and unlabeled components of the sample.

Career Highlights

Niklas has worked with notable companies in the biotechnology sector, including Miltenyi Biotec B.V. & Co. KG and Miltenyi Biotec, GmbH. His experience in these organizations has contributed to his expertise in developing advanced technologies for cell therapy.

Collaborations

Throughout his career, Niklas has collaborated with esteemed colleagues such as Stefan Miltenyi and Winfried Schimmelpfennig. These partnerships have further enriched his work and innovations in the field.

Conclusion

Niklas Elmar Neuschaefer's contributions to cell therapy manufacturing through his patents and collaborations highlight his role as a key innovator in the biotechnology industry. His work continues to pave the way for advancements in patient-specific treatments.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…